Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meriva (Curcuminoids) for Gastric Carcinogenesis Chemoprevention
NCT02782949Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2017
- Primary completion
- Oct 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in gastric cancer (GC) comparing Arm I (curcumin) with Arm II (placebo) (2 arms). Primary endpoint: Interleukin 1beta Cytokine Levels in the Gastric Mucosa at 6 months. Started Apr 2017; status: active, not recruiting.
02
Drugs
curcumin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02782949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02782949.